Home » Topics » BioWorld Science

BioWorld Science
RSS

AstraZeneca announces initiation of phase III DARE-19 study of Farxiga in COVID-19

April 24, 2020

ARRB1 shows a tumor-suppressive function in T-ALL by promoting NOTCH1 degradation

April 24, 2020

Cyp2c44 protects against breast tumor growth and metastasis by preventing PGE2 synthesis in mice

April 24, 2020

Favorable safety seen with MERS-CoV vaccine MVA-MERS-S in phase I study

April 24, 2020

Phase IIb study of Rivelin-CLO achieves primary endpoint

April 24, 2020

FDA clears IND for phase I trials of ImmuneOncia's IMC-002

April 23, 2020

Investigator-initiated trial to study Insmed's brensocatib for severe COVID-19

April 23, 2020

Amryt closes enrollment in phase III EASE trial of AP-101 for epidermolysis bullosa

April 23, 2020

Oncorus enrolling in first-in-human trial of oncolytic immunotherapy ONCR-177

April 23, 2020

FDA approves Trodelvy for previously treated metastatic TNBC

April 23, 2020

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...